US FDA grants orphan status for omacetaxine

26 January 2009

The USA's ChemGenex Pharmaceuticals says that the Food and Drug Administration has granted Orphan Drug designation to omacetaxine for  the treatment of myelodysplastic syndromes.

MDS describes a group of bone marrow disorders that are characterized by  a defect in stem cells. It is most common in elderly patients as they  are more prone to bone marrow damage but it can occur in any age group.  Approximately 15,000 people per year in the USA are diagnosed with MDS,  making its overall annual incidence five cases per hundred thousand  people.

Hagop Kantarjian, chairman of the Department of Leukemia at MD Anderson  Cancer Center in Houston, Texas, said: "MDS is a very important blood  disorder with significant unmet clinical needs in patients who fail  approved therapies. Published data has demonstrated the clinical  activity of omacetaxine in this patient population and we look forward  to future possible clinical trials to consolidate our understanding of  this product in the treatment of MDS."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight